Combined administration of drugs can improve efficacy and reduce toxicity; therefore, this combination approach has become a routine method in
cancer therapy. The main combination regimens are sequential, mixed (also termed "cocktail"), and co-loaded; however, other combinations, such as administration of synergistic drugs and the use of formulations with different mechanisms of action, may exert better
therapeutic effects. Tumor-associated macrophages (TAMs) play functional roles throughout
tumor progression and exhibit characteristic phenotypic plasticity.
Sialic acid (SA)-modified
epirubicin liposomes (S-E-L) and SA-modified
zoledronate liposomes (S-Z-L) administered separately kill TAMs, reverse their phenotype, and achieve antitumor effects. In this study, we examined the effects of a two-treatment combination for
drug delivery, using sequential, mixed, and co-loaded
drug delivery. We found that
therapeutic effects differed between administration methods: mixed administration of S-E-L and S-Z-L, co-loaded administration of SA-modified
liposomes (S-ZE-C), and sequential administration of S-E-L injected 24 h after S-Z-L did not inhibit
tumor growth; however, sequential administration of S-Z-L injected 24 h after S-E-L resulted in no
tumor growth, no toxicity to noncancerous tissue, and no death of mice, and exhibited 25%
tumor shedding. Thus, our results thus encourage the further development of combined
therapies for nanomedicines based on the mechanisms investigated here.